Inventor · disambiguated record
Vincent Brichard
Also filed as: BRICHARD VINCENT
20 granted patents·5 pending applications·366 citations·filing 1993–2010
95Inventor score
Files withLUDWIG INST CANCER RES17BRICHARD VINCENT3GLAXOSMITHKLINE BIOLOG SA2INST NAT SANTE RECH MED2BLAIS NORMAND1
Top patents by PatentIndex Score
25 records- 0190US5620886AIsolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2LUDWIG INST CANCER RES·Filed 1993·Granted Apr 15, 1997·75 cites·13 claims
- 0288US8309096B2Fusion proteinBLAIS NORMAND·Filed 2009·Granted Nov 13, 2012·11 cites·5 claims
- 0379US6669946B2Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of human leukocyte antigen tyrosinase derived peptides, and methods for treating said individualsLUDWIG INST CANCER RES·Filed 2001·Granted Dec 30, 2003·5 cites·1 claims
- 0479US5487974AMethod for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cellsLUDWIG INST CANCER RES·Filed 1993·Granted Jan 30, 1996·59 cites·6 claims
- 0573US5747271AMethod for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of HLA-A2/tyrosinase derived peptides, and methods for treating said individualsLUDWIG INST CANCER RES·Filed 1996·Granted May 5, 1998·39 cites·2 claims
- 0671US5821122AIsolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereofLUDWIG INST CANCER RES·Filed 1995·Granted Oct 13, 1998·17 cites·16 claims
- 0769US6201111B1Methods for treating subjects with disorders characterized by expression of tumor rejection antigen precursorsLUDWIG INST CANCER RES·Filed 1999·Granted Mar 13, 2001·15 cites·1 claims
- 0869US5856091AIsolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2LUDWIG INST CANCER RES·Filed 1995·Granted Jan 5, 1999·16 cites·21 claims
- 0969US5744316AIsolated, tyrosinase derived peptides and uses thereofLUDWIG INST CANCER RES·Filed 1996·Granted Apr 28, 1998·28 cites·10 claims
- 1066US5854203ATumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2LUDWIG INST CANCER RES·Filed 1995·Granted Dec 29, 1998·25 cites·2 claims
- 1166US5530096AIsolated, tyrosinase derived peptides and uses thereofLUDWIG INST CANCER RES·Filed 1994·Granted Jun 25, 1996·22 cites·1 claims
- 1257US5837476AMethods for determining disorders by assaying for a non-tyrosinase, tumor rejection antigen precursorLUDWIG INST CANCER RES·Filed 1998·Granted Nov 17, 1998·19 cites·2 claims
- 1356US2010008980A1Use of MAGE A3-Protein D Fusion Antigen in Immunotherapy Combined with Surgery, Chemotherapy or Radiotherapy for the Treatment of CancerBRICHARD VINCENT·Filed 2008·Application pending·0 cites
- 1452US6001975APrecursor processed to at least one tumor rejection antigen presented by HLA-A2LUDWIG INST CANCER RES·Filed 1998·Granted Dec 14, 1999·15 cites·1 claims
- 1552US5519117AIsolated, tyrosinase derived peptides and uses thereofLUDWIG INST CANCER RES·Filed 1994·Granted May 21, 1996·10 cites·2 claims
- 1651US2009186049A1Method of treating mage positive cancerBRICHARD VINCENT·Filed 2007·Application pending·0 cites
- 1748US5886145AIsolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereofINST NAT SANTE RECH MED·Filed 1997·Granted Mar 23, 1999·6 cites·6 claims
- 1848US2007243196A1Mage-3 and NY-ESO-1 Based Polyvalent Vaccine for Cancer ImmunotherapyGLAXOSMITHKLINE BIOLOG SA·Filed 2005·Application pending·0 cites
- 1941US5843688AIsolated tyrosinase derived peptides and uses thereofLUDWIG INST CANCER RES·Filed 1996·Granted Dec 1, 1998·2 cites·3 claims
- 2036US2011070268A1MethodGLAXOSMITHKLINE BIOLOG SA·Filed 2010·Application pending·0 cites
- 2135US2010021424A1Method For Identifying Whether A Patient Will Be Responder or Not to ImmunotherapyBRICHARD VINCENT·Filed 2007·Application pending·0 cites
- 2233US6096520ABrain glycogen phosphorylase cancer antigenLUDWIG INST CANCER RES·Filed 1998·Granted Aug 1, 2000·2 cites·24 claims
- 2330US5958711AMethods for determining expression of NAG tumor rejection antigen precursorINST NAT SANTE RECH MED·Filed 1998·Granted Sep 28, 1999·0 cites·2 claims
- 2430US5843687AIsolated, tyrosinase derived peptides and uses thereofLUDWIG INST CANCER RES·Filed 1995·Granted Dec 1, 1998·0 cites·7 claims
- 2529US6284476B1Method of identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of human leukocyte antigen/tyrosinase derived peptides, and methods for treating said individualsLUDWIG INST CANCER RES·Filed 1995·Granted Sep 4, 2001·0 cites·3 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →